Boosting the Body's fight: new therapy aims to recharge Cancer-Killing cells in tough leukemia
NCT ID NCT06389305
Summary
This study is for children and young adults (ages 1-39) whose B-cell acute lymphoblastic leukemia has come back or hasn't responded to treatment, and whose previous CAR-T cell therapy stopped working early. Researchers want to see if adding a different type of immune cell, called CIK cells, can help control the cancer for longer by supporting the exhausted CAR-T cells. Patients will be randomly assigned to receive either standard care, CIK cells, or a modified version of CIK cells to compare their survival and how long the cancer stays away.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.